Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative have provided an enrollment update for the (Z)-Endoxifen arm of the ongoing I-SPY 2 clinical trial. Six patients have been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive i..
Heligenics, a biotech company based in Las Vegas, has developed a first-of-its-kind precision genetic test that can select among drugs to treat breast cancer. The test uses Heligenics' proprietary GigaAssay technology to identify which of the 10,000 potential mutations in a cancer gene would make a patient susceptible to a drug they would want to take and which variants produced resistance to th..
Daré Bioscience has announced the publication of Phase 1/2 clinical study results for its investigational formulation, DARE-VVA1. The tamoxifen-based product is designed to treat vulvovaginal atrophy (VVA) in women without hormones and was found to be safe and well-tolerated in postmenopausal participants with moderate to severe VVA. Daré is developing DARE-VVA1 as a hormone-free option for pati..
